MedPath

Lanzhou Institute Of Biological Products Co., Ltd.

Lanzhou Institute Of Biological Products Co., Ltd. logo
🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

6

Active:0
Completed:1

Trial Phases

3 Phases

Phase 1:2
Phase 3:3
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 3
3 (50.0%)
Phase 1
2 (33.3%)
Not Applicable
1 (16.7%)

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection

Not Applicable
Conditions
Tetanus
Interventions
Drug: Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection
Drug: Placebo
First Posted Date
2025-09-02
Last Posted Date
2025-09-02
Lead Sponsor
Lanzhou Institute of Biological Products Co., Ltd
Target Recruit Count
68
Registration Number
NCT07149454
Locations
🇨🇳

Lanzhou Institute of Biological Products Co., Ltd., Lanzhou, Gansu, China

Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL

Phase 1
Conditions
Lymphoma, Non-Hodgkin
Lymphoma, T-Cell
First Posted Date
2022-09-28
Last Posted Date
2022-09-28
Lead Sponsor
Lanzhou Institute of Biological Products Co., Ltd
Target Recruit Count
71
Registration Number
NCT05557903
Locations
🇨🇳

Jiangsu Provincial People's Hospital, Najing, Jiangsu, China

A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB)

Phase 3
Conditions
Overactive Bladder
Interventions
First Posted Date
2016-06-01
Last Posted Date
2018-01-03
Lead Sponsor
Lanzhou Institute of Biological Products Co., Ltd
Target Recruit Count
216
Registration Number
NCT02786407

A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine

Phase 1
Conditions
Meningococcal Meningitis
First Posted Date
2015-06-25
Last Posted Date
2015-06-25
Lead Sponsor
Lanzhou Institute of Biological Products Co., Ltd
Target Recruit Count
200
Registration Number
NCT02481232
Locations
🇨🇳

Hubei CDC, Wuhan, Hubei, China

A Study to Evaluate Botulinum Toxin Type A for Injection(HengLi®)for Prophylactic Treatment of Chronic Migraine

Phase 3
Conditions
Chronic Migraine
Interventions
First Posted Date
2014-11-14
Last Posted Date
2018-01-03
Lead Sponsor
Lanzhou Institute of Biological Products Co., Ltd
Target Recruit Count
288
Registration Number
NCT02291380
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.